Friday, August 12, 2016

Ablynx Nv. University and Research Institutes

Ablynx Nv. University and Research Institutes



Ablynx is a pioneer in the discovery and development of a novel class of therapeutic proteins known as Nanobodies®. The structure and extreme stability of Nanobodies® enables them to engage therapeutic targets that are inaccessible to conventional antibodies. Nanobodies® therefore address the strong and growing demand for improved therapeutics for serious and life-threatening diseases, and have the potential to create new market opportunities beyond those accessible to conventional antibodies.
Since commencing operations in 2002, Ablynx has generated Nanobody® leads against a number of human disease targets across a wide range of therapeutic areas. Two of these leads are now in advanced pre-clinical development, and Ablynx’s first therapeutic program is expected to enter human clinical trials in 2006.

No comments:

Post a Comment